JP Morgan Chase’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

JP Morgan Chase’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,535	Closed	-$12K	–	5935
2020 Q1	$12K	Sell	4,535 -109	-2%	-$179	﹤0.01%	5032
2019 Q4	$5K	Buy	4,644 +8	+0.2%	+$13	﹤0.01%	5485
2019 Q3	$8K	Buy	4,636 +752	+19%	+$2.29K	﹤0.01%	5533
2019 Q2	$18K	Sell	3,884 -103,853	-96%	-$582K	﹤0.01%	5471
2019 Q1	$696K	Buy	107,737 +98,974	+1,129%	+$518K	﹤0.01%	4013
2018 Q4	$44K	Buy	8,763 +7,302	+500%	+$51.1K	﹤0.01%	5129
2018 Q3	$12K	Sell	1,461 -54,739	-97%	-$607K	﹤0.01%	5490
2018 Q2	$708K	Buy	+56,200	New	+$770K	﹤0.01%	4000

JP Morgan Chase's NTGN Position: Q2 2020 in Review

JP Morgan Chase sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 4,535 shares — an estimated $12K sold.

JP Morgan Chase first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $708K in Q2 2018. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

JP Morgan Chase reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
JP Morgan Chase sold 4,535 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $12K.
JP Morgan Chase first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
JP Morgan Chase's Neon Therapeutics, Inc. Common Stock position peaked at $708K in Q2 2018.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.